Genentech buys Regor's next-gen CDK inhibitors for $850M
Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment of $850 million, the companies announced today. …